National Headache Fo
National Headache Foundation Makes WorkMigraine Program Resources Free to the Public
05 janv. 2023 15h18 HE | National Headache Foundation
Chicago, Illinois, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The National Headache Foundation (NHF) announced it is now making available free to the public its proven WorkMigraine program to help employers...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
05 août 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Record Second Quarter 2022 Financial Results
04 août 2022 16h05 HE | electroCore, Inc.
Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and webcast today, August 4, 2022 at 4:30 pm EDT ...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Second Quarter 2022 Financial Results on August 4
28 juil. 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome
07 juil. 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
24 mai 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Upcoming Investor Conferences
18 mai 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Record First Quarter 2022 Financial Results
05 mai 2022 16h00 HE | electroCore, Inc.
First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce First Quarter 2022 Financial Results on May 5
28 avr. 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Completes Sale of New Jersey Tax Benefits
26 avr. 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its...